# A Study of LY2140023 in Hepatically-Impaired Participants

> **NCT01475136** · PHASE1 · COMPLETED · sponsor: **Denovo Biopharma LLC** · enrollment: 37 (actual)

## Conditions studied

- Hepatic Insufficiency

## Interventions

- **DRUG:** LY2140023

## Key facts

- **NCT ID:** NCT01475136
- **Lead sponsor:** Denovo Biopharma LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2021-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01475136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01475136, "A Study of LY2140023 in Hepatically-Impaired Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01475136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*